6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
Evidence-based guide to thymosin alpha-1 (thymalfasin) dosing considerations in Black and African ancestry populations, covering pharmacogenomics, immune response variability, and clinical monitoring.
Evidence-based guide to thymosin alpha-1 (thymalfasin) dosing in Hispanic and Latino patients, covering pharmacogenomics, diabetes comorbidity, CYP variants, and clinical decision frameworks.
Evidence-based review of Thymosin Alpha-1 (thymalfasin) efficacy differences in East Asian populations, including pharmacogenomic factors, HBV trial data, and dosing considerations.
Evidence-based review of Thymosin Alpha-1 (thymalfasin) efficacy differences in South Asian populations, covering pharmacogenomics, dosing considerations, immune response variation, and clinical trial subgroup data.
Evidence-based review of thymosin alpha-1 (thymalfasin) safety, pharmacogenomics, and dosing considerations specific to Black and African ancestry populations, including G6PD prevalence, immune response variation, and monitoring recommendations.
A review of what is and is not known about thymosin alpha-1 (thymalfasin) use in South Asian patients, covering baseline disease burden, pharmacogenomic plausibility, and where the evidence runs out. Evidence gaps are flagged rather than filled with unverifiable citations.